The recent discovery that brain metastases in HER2+ breast cancer patients rely on FASN [82, 83] illuminates the important translational impact of combining blood–brain–barrier penetrable versions of FASNis and BCL-2 BH3 mimetics such as venetoclax, which has already shown a potential efficacy in the treatment of malignancies with central nervous system involvement [84–86]. Here, BCL2 is linked to breast cancer.